Lipoprotein(a) [Lp(a)] is a powerful, genetically determined and frequently overlooked driver of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Although elevated Lp(a) affects up to 1 in 5 individuals worldwide, it remains a blind spot in primary prevention—rarely measured, often misunderstood, and not captured by routine risk calculators. As a result, many high-risk patients continue to accumulate preventable “residual risk”.

This 60-minute, highly practical, case-based webinar brings clarity to one of the most important—and most confusing—areas in contemporary cardiovascular prevention. Led by world-renowned experts in cardiology, lipidology, endocrinology, and clinical pharmacotherapy, the session will equip you with a step-by-step clinical approach you can use immediately in practice.

Participants will learn who should be screened, how to interpret Lp(a) results as risk-enhancing factors, and how to tailor preventive strategies when Lp(a) is elevated. The programme will also address the uncomfortable truth: current therapies have minimal impact on Lp(a) levels. As such, clinicians must master the art of aggressive optimisation of all other cardiovascular risk factors while preparing for the arrival of potent, targeted Lp(a)-lowering therapies now in late-stage development.

The session concludes with a 30-minute interactive case discussion, ensuring you walk away confident in applying guideline-based, real-world strategies for primary prevention.

Why Attend? — Key Benefits for Participants

✓ Gain a clear, evidence-based framework for when and whom to screen for Lp(a)
✓ Understand the causal role of Lp(a) in atherothrombosis and why traditional risk calculators fail to detect its impact
✓ Learn how to use Lp(a) as a risk-enhancing factor to refine ASCVD risk assessment and decide on preventive intensity
✓ Understand the limits of current therapies (statins, PCSK9 inhibitors, lifestyle) on Lp(a)
✓ Discover how to optimise global cardiovascular risk when Lp(a) is high
✓ Get an early look at emerging ASO/siRNA Lp(a)-lowering drugs and their expected clinical role
✓ Apply all concepts directly through a case-based, interactive discussion
✓ Earn valuable, practical knowledge you can apply the next day in your clinic

Ideal Audience

This free webinar is designed for all healthcare professionals involved in cardiovascular risk assessment and primary prevention, including:

• Primary care physicians & general practitioners

• Cardiologists & internal medicine specialists

• Endocrinologists & lipidologists

• Clinical pharmacists & advanced practice providers

• Nurse practitioners & physician assistants

• Cardiometabolic and preventive medicine teams

• Dietitians & lifestyle medicine practitioners

• Multidisciplinary clinicians managing high-risk patients

Whether you are new to Lp(a) or already familiar with its challenges, this session will give you the clarity, confidence, and practical tools needed to integrate Lp(a) into routine preventive care.